Micro RNA


MicroRNAs constitute a recently discovered class of non-coding RNAs that play key roles in the regulation of gene expression. According to the International Agency for Research on Cancer (IARC), a specialized agency of the WHO, about 12.7 million new cancer cases were reported in 2008 and the number reached 14.1 million in 2012. MicroRNAs are used as a biomarker for cancer diagnosis and treatment. Some of the major companies operating in the global microRNA market are Affymetrix Inc., Alnylam Pharmaceuticals Inc., Santaris Pharma A/S, Exiqon A/S, AstraZeneca Pharmaceuticals LP, Biogen Idec Inc., Eli Lilly and Co., Pfizer Inc., CBC Comprehensive Biomarker Center GmbH, F. Hoffman-La Roche, GlaxoSmithKline, Merck & Co. Inc., Novartis AG and Sigma-Aldrich. GlaxoSmithKline (GSK) has established collaboration with Regulus Therapeutics to develop and commercialize therapeutics targeting microRNA-122 for hepatitis C virus (HCV) infection.


  • Biogenesis
  • Cellular functions
  • Non-coding RNAs

Related Conference of Micro RNA

April 16-17, 2026

19th World Congress on Stem Cell Research

Tokyo, Japan
June 08-09, 2026

9th Global Conference on Cell and Gene Therapy

Rome, Italy
June 15-16, 2026

22nd Global Summit on Stem Cell & Regenerative Medicine

Amsterdam, Netherlands
June 15-16, 2026

13th World Congress on Epigenetics and Chromosome

Paris, France
June 18-19, 2026

19th International Conference on Genomics & Pharmacogenomics

Singapore City, Singapore
September 25-26, 2025

6th Annual summit on Cell Signaling and Cancer Therapy

Montreal, Canada

Micro RNA Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in